Comparative Efficacy of Lixisenatide and Liraglutide on glucose variability and safety in CGM in Type 2 Diabetes with long-acting insuli
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000020509
- Lead Sponsor
- niversity of Fukui
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with type 1 diabetes, patients with severe hypoglycemia, patients with severe liver disease, patients with severe renal disease, patients with severe heart disease, patients with history of myocardial infarction within 6 months, patients with severe pancreatic disease, cancer patients, patients with severe diabetic neuropathy, patients with severe diabetic retinopathy, patients with severe ketosis and in a coma, patients with history of digestive diseases, patients with history of gastrectomy, patients with lactose intolerance, heavy drinkers, patients using steroid, pregnant patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MAGE(Mean amplitude of glycemic excursion) of more than 10 days after thrapeutic intervention
- Secondary Outcome Measures
Name Time Method data in CGM (mean blood glucose, SD, pre-meal plasma glucose in point of care testing, M-value, hypoglycemic index), fasting plasma glucose, 1 hour post prandial glucose, 2 hour post prandial glucose, lipid profile, blood pressure, heart rate, side effect